Markers of bone turnover in bone metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2952-2960

  Fontana, A ^a   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonate treatment; Bone marker; Bone matrix; Bone metastases; Pyridinium

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; PYRIDINIUM DERIVATIVE;

BONE METASTASIS; BONE TURNOVER; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; OSSIFICATION; OSTEOLYSIS; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034660097     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2952::aid-cncr11>3.0.co;2-m     Document Type: Conference Paper

References (67)

1. Hiraga T, Nakajima T, Ozawa H. Bone resorption induced by a metastatic human melanoma cell line. Bone 1995;16:349-56.
2. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1986;186:315-20.
3. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77,4:1046-53.
4. Gomez B, Ardakanis S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, et al. Monoclonal antibody assay for measuring bone specific alkaline phosphatase in serum. Clin Chem 1995;41: 1560-6.
5. Price PA. Vitamin K-dependent bone proteins. In: DV Cohn, TJ Martin, PJ Meunier, editors. Calcium regulation and bone metabolism. Basic and clinical aspects. New York: Elsevier Science Publishers, 1987;9:419-26.
6. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. J Clin Invest 1980;66:878-83.
7. Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ.. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984;i:1091-3.
8. Charles P, Poser JW, Mosekilde L, Jensen FT. Estimation of bone turnover evaluated by 47 calcium kinetics. Efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 1985;76:2254-8.
9. Delmas PD, Malaval L, Arlot ME, Meunier PJ. Serum bone gla-protein compared to bone histomorphometry in endocrine diseases. Bone 1985;6:329-41.
10. Bataille R, Delmas PD, Sany J. Serum bone gla-protein in multiple myeloma. Cancer 1987;59:329-34.
11. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;2: 255-64.
12. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36.
13. Hassager C, Fabbri-Mabelli G, Christansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type 1 collagen. Osteoporosis Int 1993;3:50-2.
14. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992;7:1243-50.
15. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bettica P, Baylink DJ. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 1993;39:2254-8.
16. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, et al. Immunoassay for intact amino-terminal propeptide of huùan type I procollagen. Clin Chem 1996;42: 947-54.
17. Tahtela R, Tholix E. Serum concentration of type I of collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996;16:2289-94.
18. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995;80:97-103.
19. Prockop DJ, Kivirikko KI, Tuderman K, Guzman NA.. The biosynthesis of collagen ant its disorders. N Engl J Med 1979;301:13-23.
20. Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic disease. Endocrinol Metab Clin North Am 1990;19:1-18.
21. Eyre DR, Dickson IR, Van Ness KP. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988;252:495-500.
22. Colwell A, Eastell R. Renal clearance of free and conjugated pyridinium crosslinks of collagen. J Bone Miner Res 1996;11: 1976-80.
23. Seyedin S, Zuk R, Kung V, Hesley RP, Gomez B, Nielsen LA, et al. An immunoassay to urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635-42.
24. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ.. Direct, enzyme-linked immunoassay for urinary deoxypyridinolin as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
25. Hanson DA, Weiss MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR.. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
26. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.Clin Chem 1993;39:635-40.
27. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
28. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
29. Hassager C, Jensen LT, Podenphant I, Thomsen K, Christiansen C.. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of Nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994;54:30-3.
30. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992;74:476-80.
31. Alexandersen P, Schlemmer A, Riis BJ, Christiansen C. Circadian variation in Crosslaps™. A new marker of bone resorption. J Bone Miner Res 1994;9:S1-190.
32. Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, et al. Clinical evaluation of the serum Crosslaps One Step Elisa, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998;44:2290-300.
33. Bianco P, Fisher LW, Young MF, Termine JD, Gehron Robey P. Expression of bone sialoprotein (BSP) in human developing skeletal and nonskeletal tissues as revealed by immunostaining and in situ hybridisation. Calcif Tissue Int 1991;49: 421-6.
34. Masi L, Brandi ML, Robey PG, Crescioli C, Calvo JC, Bernabei P, et al. Biosynthesis of bone sialoprotein by human osteoclast-like cell line (FLG 29.1). J Bone Miner Res 1995; 10:187-96.
35. Seibel MJ, Woitge HG, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996; 81:3289-94.
36. Wolfgang W, Armbruster FP, Karmatschek M, Reinauer H.Bone sialoprotein in serum of patients with malignant bone diseases. Clin Chem 1997;43:85-91.
37. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14:792-801.
38. Diel IJ, Solomayer EF, Pfeilschifter J, Seibel MJ, Gollan C, Conradi R, et al. Serum bone sialoprotein and crosslaps are both highly predictive for bone metastases in breast cancer. Cancer-induced bone disease, Second International Conference, March 27-29, 1999, Davos, Abstract 36.
39. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997;75:408-12.
40. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A.. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 1991;64:884-6.
41. Massidda B, Ionta MT, Foddi MR, Mascia L, Bruder F, Aloi MB, et al. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma. Anticancer Res 1996;16:2221-4.
42. Nguyen-Pamart M, Bonneterre M, Hecquet B. Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res 1995;15:1601-4.
43. Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M, et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer 1994;70:701-3.
44. Nemoto R, Nakamura I, Nishijima Y, Shiobara K, Shimizu M, Takehara T, et al. Serum pyridinoline crosslinks as markers of tumor-induced bone resorption. Br J Urol 1997;80:274-80.
45. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. New resorption markers for the management of patients with bone metastases from prostate cancer. Bone 1998;23: SA218.
46. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996; 69:350-3.
47. Koizumi M, Yamada Y, Takigushi T, Nomura E, Furukawa M, Kitahara T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995;121:542-8.
48. Berruti A, Torta M, Piovesan A, Raucci CA, Orlandi F, Panero A, et al. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 1995; 15:2871-6.
49. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 1996;73:1581-7.
50. Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, et al. Use of bone turnover marker, pyridinoline croos-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 1999;39:1-7.
51. Zaninotto M, Secchiero S, Rubin D. Serum bone alkaline phosphatase in the follow-up of skeletal metastases. Anticancer Res 1995;15:2223-8.
52. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnostic of bone metastasis in prostate cancer. J Urol 1996;155:1348-51.
53. Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26:625-32.
54. Wolff JM, Ittel TH, Borchers H, Boekels O, Jakse G. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999;19:2653-5.
55. Kamby C, Egsmose C, Söletormos G, Dombernowsky P. The diagnostic and prognostic value of serum bone GLA protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest 1993;53:439-46.
56. Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, et al. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol 1988;24:1211-7.
57. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S, Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of bone metastases. Clin Biochem 1996;29:67-72.
58. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-14.
59. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone GLA protein levels in multiple myeloma. Cancer 1990; 66:167-72.
60. Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undertermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997;90:3743-50.
61. Pecherstorfer M, Seibel MJ, Hoyle NR, Woitge HW, Keck A, Horn F, et al. Bone resorption in multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) quantified by serum levels of crosslaps. Cancer-induced bone disease, Second International Conference, March 27-29, 1999, Davos, abstract 52.
62. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I of collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
63. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996;32A:1166-70.
64. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S.Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999;62:300-6.
65. Vinholes JJF, Praskash Purohit O, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243-50.
66. Luftner D, Gunther S, Flath B, Muller C, Echteroff K, Mergenthaler HG, et al. The course of the urinary DPD-crosslink secretion in metastatic breast cancer: a possibility for response assessment. Anticancer Res 1999;19:2537-44.
67. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 1997;80:1760-7.